<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01427114</url>
  </required_header>
  <id_info>
    <org_study_id>KUH1010258</org_study_id>
    <nct_id>NCT01427114</nct_id>
  </id_info>
  <brief_title>R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML)</brief_title>
  <official_title>Open-labeled, Multicenter Phase II Study of Rituximab, Cyclophosphamide, Vincristine, and Prednisolone (R-CVP) Chemotherapy in Patients With Non-conjunctival Ocular Adnexal MALT Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Konkuk University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul St. Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Konkuk University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine how efficient the combination of rituximab,&#xD;
      cyclophosphamide, vincristine, and prednisolone (R-CVP) is in the treatment of stage I or II&#xD;
      non-conjunctival ocular adnexal MALT lymphoma (OAML).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment of stage I or II OAML is mainly composed of radiotherapy because chemotherapy&#xD;
      including cyclophosphamide, vincristine, and prednisolone (CVP) did not show the acceptable&#xD;
      response rate compared with radiotherapy. However, radiotherapy for this disease can cause&#xD;
      many complications of eyes. This clinical trial was designed to examine the efficacy of R-CVP&#xD;
      combination therapy as a first-line treatment for stage I or II non-conjunctival OAML aiming&#xD;
      to avoid radiation hazard and increase the efficacy of CVP chemotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2011</start_date>
  <completion_date type="Actual">January 1, 2021</completion_date>
  <primary_completion_date type="Actual">August 1, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete response rate</measure>
    <time_frame>3 years</time_frame>
    <description>CR rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>5 years</time_frame>
    <description>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>R-CVP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 cycles of R-CVP followed by 2 cycles of rituximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab, cyclophosphamide, vincristine, and prednisolone</intervention_name>
    <description>6 cycles of R-CVP followed by 2 cycles of rituximab</description>
    <arm_group_label>R-CVP</arm_group_label>
    <other_name>6 cycles of R-CVP followed by 2 cycles of rituximab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed OAML&#xD;
&#xD;
          -  Non-conjunctival or bilateral conjunctival (TNM-based, above T1N0M0 or bT1N0M0), Ann&#xD;
             Arbor stage I and II OAML&#xD;
&#xD;
          -  Previously untreated&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Performance status: ECOG 0-2&#xD;
&#xD;
          -  Adequate hematological function: hemoglobin ≥9 g/dL,, absolute neutrophil count (ANC)&#xD;
             ≥1,500/μL, and platelet count ≥100,000/μL, unless abnormalities are due to bone marrow&#xD;
             involvement by the lymphoma&#xD;
&#xD;
          -  Adequate liver function tests:&#xD;
&#xD;
             i. Transaminase (AST/ALT) &lt;3 times the upper normal value ii. Bilirubin &lt;2 times the&#xD;
             upper normal value&#xD;
&#xD;
          -  Adequate renal function:serum creatinine level &lt;2 mg/dL (177 μmol/L)&#xD;
&#xD;
          -  Life expectancy ≥ 6 months&#xD;
&#xD;
          -  A negative serum or urine pregnancy test before treatment must be available for both&#xD;
             premenopausal women and for women who have &lt;2 years after the onset of menopause.&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  NHL subtypes other than OAML&#xD;
&#xD;
          -  Primary conjunctival OAML, unilateral involved (T1N0M0)&#xD;
&#xD;
          -  Ann Arbor stage III or IV&#xD;
&#xD;
          -  CNS involvement by the lymphoma or any evidence of spinal cord compression. Brain&#xD;
             CT/MRI is only mandatory (within 4 weeks) with clinical suspicion of CNS involvement&#xD;
             by the lymphoma&#xD;
&#xD;
          -  Pregnant or lactating women, women of child-bearing potential not using adequate&#xD;
             contraception&#xD;
&#xD;
          -  Inadequate liver function tests:&#xD;
&#xD;
             i. Transaminase (AST/ALT) ≥3 times the upper normal value or ii. Bilirubin ≥2 times&#xD;
             the upper normal value&#xD;
&#xD;
          -  Inadequate renal function:&#xD;
&#xD;
             i. serum creatinine level &lt;2 mg/dL (177 μmol/L)&#xD;
&#xD;
          -  Other serious illness or medical conditions i. Unstable cardiac disease despite&#xD;
             treatment; myocardial infarction within 6 months prior to study entry ii. History of&#xD;
             significant neurological or psychiatric disorders including dementia or seizures&#xD;
&#xD;
          -  Active uncontrolled infection (HIV, hepatitis B, Hepatitis C, active Tuberculosis,&#xD;
             active bacterial, or active fungal infection)&#xD;
&#xD;
          -  Any other malignancies within the past 5 years except for curatively treated&#xD;
             non-melanoma skin cancer or in situ carcinoma of the cervix uteri&#xD;
&#xD;
          -  Known hypersensitivity to any of the study drugs or its ingredients (i.e.,&#xD;
             hypersensitivity to Polysorbate 20, CHO cell products, or recombinant human&#xD;
             antibodies)&#xD;
&#xD;
          -  Concomitant administration of any other experimental drug under investigation or&#xD;
             concomitant chemotherapy, hormonal therapy, or immunotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seok-Goo Cho, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul St. Mary's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sung-Yong Kim, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Konkuk University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KonKuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>143-729</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 30, 2011</study_first_submitted>
  <study_first_submitted_qc>August 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2011</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Konkuk University Medical Center</investigator_affiliation>
    <investigator_full_name>Sung-Yong Kim</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>extranodal marginal zone lymphoma</keyword>
  <keyword>ocular adnexal lymphoma</keyword>
  <keyword>mucosa associated lymphoid tissue</keyword>
  <keyword>cyclophosphamide</keyword>
  <keyword>vincristine</keyword>
  <keyword>prednisolone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

